Journal article
Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma
Abstract
Importance: The recent development of targeted therapy and immunotherapy has made neoadjuvant therapy an attractive option for patients with hepatocellular carcinoma (HCC). However, surgeons are concerned that adverse effects of neoadjuvant therapy with these agents could lead to delayed or even cancelled surgeries.
Objective: To summarize the current evidence regarding toxicity profiles for tyrosine kinase inhibitors (TKIs) and immune …
Authors
Griffiths CD; Zhang B; Tywonek K; Meyers BM; Serrano PE
Journal
JAMA Network Open, Vol. 5, No. 7,
Publisher
American Medical Association (AMA)
Publication Date
July 1, 2022
DOI
10.1001/jamanetworkopen.2022.22721
ISSN
2574-3805